mRNA cocktail clears tumors in about half of mice

In the Ruscetti Lab, a single injection gave mouse immune systems two jobs at once: enter a pancreatic tumor and learn what to attack. About 50% of treated mice had complete tumor responses and remained disease-free for up to a year after treatment stopped, according to work by Marcus Ruscetti and Chaitanya Naimesh Parikh at UMass Chan Medical School.

The target is pancreatic ductal adenocarcinoma, the most common and aggressive type of pancreatic cancer. It is often detected after spreading: the five-year survival rate for stage IV disease is 3%, while the overall survival rate across stages is 13%. Earlier immunotherapy efforts using cytokines—small proteins that recruit and activate immune cells—could trigger dangerous, system-wide reactions without eliminating most tumors.

The new cocktail combines five cytokine mRNAs with three tumor-associated antigen mRNAs. Messenger RNA is a temporary copy of genetic instructions that cells use to make proteins. Here, the cytokine sequences supply immune signals, while the antigen sequences help the immune system recognize pancreatic cancer cells as foreign. In mouse models, the treatment reduced fibrotic material around tumors and increased tumor cell necrosis.

The durable responses may indicate that the mice developed immune memory against the cancer, although that interpretation still comes from animal experiments. The study was published in Nature Communications, and the researchers are developing a potential IND-ready product—a treatment prepared for the regulatory filing needed before clinical testing.

For patients, the concrete change is not a new treatment available today. It is a candidate that has cleared an early biological hurdle in mice: roughly half of the treated animals stayed disease-free for a year after dosing ended. The next test is whether the same combination can be made safe and effective in people; the researchers are preparing for future clinical trials, but no human results are reported.